The Patent Finder

Formulations of ANTI-CD38 Antibodies for Subcutaneous Administration

Sanofi-Aventis

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. 2 of these applications claim priority to application 62/944,082, filed Dec 5, 2019. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
PatentTitleHolderStatusExpiresTime remainingConfidence
US 12,729,244Formulations of ANTI-CD38 Antibodies for Subcutaneous Administration
In force
 · High confidence
Sanofi-Aventis U.S. LLCIn force
High confidence
US 12,780,933Formulations of ANTI-CD38 Antibodies for Subcutaneous Administration
In force
 · High confidence
Sanofi-Aventis U.S. LLCIn force
High confidence
2 of 2 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited